Pharmaceuticals
Mervyn's Petcare Marks One Year at Magnify Incubator on UCLA campus with Launch of Second Feline Supplement on Amazon
SEOUL, South Korea, Aug. 13, 2026 /PRNewswire/ -- Ari's Purrfect
Omega+Multivitamin Lickable Supplement
2026-08-13 21:00
3425
Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
NEW YORK and SUZHOU, China, Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced that it will present efficacy and safety results from a Phase 1b proof-of-concept study...
2026-08-13 19:00
3182
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been app...
2026-08-13 09:00
4450
Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026
Following REJURAN®'s TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals. GANGNEUNG, South Korea, Aug. 13, 2026 /PRNewswire/ -- PharmaResearch, the biopharmaceutical company behind REJURAN®, recently participated in Aesth...
2026-08-13 08:00
4713
Osara Health Marks 10 Years with Global Call to Make Cancer Support Beyond Treatment Standard
Launched to mark the company's 10th anniversary, Osara Health's Global Cancer Support Declaration has already secured signatures from healthcare professionals worldwide. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Osara Health, a global digital health company focused on the human experience of cance...
2026-08-12 23:17
3321
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
NANJING, China, Aug. 12, 2026 /PRNewswire/ -- August 6, the NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The ...
2026-08-12 22:00
3346
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inh...
2026-08-12 20:30
2872
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....
2026-08-12 17:38
3390
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....
2026-08-12 17:10
3365
New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
SHANGHAI, Aug. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of patients with locally adv...
2026-08-12 08:45
2847
Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging
VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging MILAN, Aug. 11, 2026 /PRNewswire/ -- Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to ...
2026-08-11 20:00
2485
Korean Biotech Company K-Medichem Expands Global Market Reach with PDRN Derma Skincare Line in Vietnam, Indonesia and Beyond
* PDRN Derma cream, serum, and mask lineup positions premium K-dermocosmetics based on patented ingredients for Southeast Asian market expansion CHUNCHEON, South Korea, Aug. 11, 2026 /PRNewswire/ -- K-Medichem Co., Ltd. (K-Medichem), a Korean biotech company built on university research, is acc...
2026-08-11 19:17
3326
Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
EAST RUTHERFORD, N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment will add adva...
2026-08-11 18:00
2593
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30,...
2026-08-11 17:45
2873
Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery
LAGUNA HILLS, Calif. and SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation f...
2026-08-11 09:30
3802
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly...
2026-08-10 19:00
4977
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...
2026-08-10 17:36
3386
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), i...
2026-08-10 12:05
2843
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
SHANGHAI, Aug. 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspect...
2026-08-10 08:00
2827
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX e...
2026-08-08 15:46
4657
Week's Top Stories
Most Reposted
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 275 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 270 media titles]
2026-10-22 11:55Carro Establishes Inaugural SGD450 Million Asset-Backed Securitisation Warehouse Facility
[Picked up by 267 media titles]
2026-10-22 11:00Ready Server Launches ReadyServer LLM API, Giving Every VPS Customer Private AI Inference at No Extra Cost
[Picked up by 265 media titles]
2026-10-20 14:10Most Read
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
2026-10-19 13:18
11371
FinDev Canada provides a USD 60 million loan to Muangthai Capital to advance gender equality and private sector investment in Thailand
2026-10-17 00:54
11260
BUUU Group Limited Announces 10-for-1 Forward Share Split
2026-10-17 04:30
10575